Retatrutide, a new dual activator of the GLP-1 binding site and glucose-dependent insulinotropic polypeptide (GIP) binding site , is exhibiting promising results in early patient studies. Ongoing https://shopretatrutidepeptide.com/retatrutide-research-knowledge-hub/